TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06655454
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention will appear to give patients an additional injection, but no additional drug will be given.
Study: NCT06587880
Drug: Bone Bioactive Liquid
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
Study: NCT06587880
Drug: Warm Saline Mouth Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
Study: NCT06592612
Drug: Second-line systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
Study: NCT04789096
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT05324774
Drug: 9MW0813
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously.
Study: NCT06590844
Drug: Injectable coenzyme I
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
Study: NCT05269160
Drug: Dermaprazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
Study: NCT05269160
Drug: Dermaprazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
Study: NCT06600880
Drug: MK-6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
Study: NCT06598969
Drug: Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
Study: NCT06598956
Drug: TQ05105
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.
Study: NCT05538507
Drug: smart soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe AD, mild or moderate AD and MCI will be given smart soup
Study: NCT05538507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with MCI will be given placebo
Study: NCT06590545
Drug: KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
Study: NCT06597799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tablets of placebo
Study: NCT05063994
Drug: Chronocort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-encapsulated hydrocortisone modified-release capsule for oral administration.
Study: NCT05715931
Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle.
Study: NCT04730804
Drug: ALXN1830
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1830 will be administered as SC infusion(s).
Study: NCT04730804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as SC infusion(s).
Study: NCT04856358
Drug: GLPG3121
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3121 modified-release tablet
Study: NCT04856358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03831152
Drug: ADV7103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single group assignment
Study: NCT05327348
Drug: Normal Saline 10 mL Injection
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
Study: NCT06235775
Drug: GV1001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT06235775
Drug: GV1001 1.12mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT05261646
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo（Stage 1；Stage 2）
Study: NCT06541665
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06326814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Study: NCT05544019
Drug: SGR-1505
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGR-1505 will be administered orally.
Study: NCT05403385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo capsule to inupadenant
Study: NCT06639711
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Study: NCT06287580
Drug: chlorthalidone 25 mg
Normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorthalidone, 25 mg orally once daily
Study: NCT06059664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
Study: NCT06015269
Drug: DC cells
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: At a single arm, 1x107cells dose
Study: NCT06654986
Drug: Placebo + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
Study: NCT06653972
Drug: Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
Study: NCT06591910
Drug: Chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Serplulimab combined with chemotherapy
Study: NCT06594692
Drug: CAPOX Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
Study: NCT06590090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
Study: NCT04592822
Drug: WD-1602
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dabigatran etexilate mesylate granules for oral suspension
Study: NCT04592822
Drug: Pradaxa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: dabigatran etexilate capsules
Study: NCT00786058
Drug: OFF in experimental arm
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
Study: NCT00000721
Drug: CD4 Antigens
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06654882
Drug: TNFi (Tumor Necrosis Factor inhibitor) medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly
Study: NCT06586866
Drug: JK-1201I
Approvals — FDA: no, EMA: no, PMDA: no
Description: JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
Study: NCT05898633
Drug: Recombinant fragment of human surfactant protein D (rfhSP-D)
Normalized name: surfactant protein-D homotrimer, recombinant fragment human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of rfhSP-D
Study: NCT06588036
Drug: Smecta
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 will be given smecta scahet
Study: NCT06723002
Drug: Atherolive 500mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Study: NCT06723002
Drug: Atherolive 1000/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Study: NCT06723002
Drug: Placbo_Atherolive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation ).
Study: NCT06599086
Drug: 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
Study: NCT06592326
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9MW2821, 1.25mg/kg, intravenous (IV) infusion
Study: NCT05502809
Drug: Deep-frozen platelets
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryopreserved platelets
Study: NCT06599762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice daily
Study: NCT06592300
Drug: Vemlidy® film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
Study: NCT05767749
Drug: lidocaine + epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
Study: NCT06599918
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Study: NCT06599918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Study: NCT06594640
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2, D2
Study: NCT06594640
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2, D2-6
Study: NCT06604065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
Study: NCT05083975
Drug: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local dental anesthetic agent
Study: NCT06004739
Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
Study: NCT05116410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated SC
Study: NCT05387239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline plus standard care
Study: NCT04856566
Drug: Low Marijuana, Hash, THC, or Grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with low amount of THC
Study: NCT04856566
Drug: High Marijuana, Hash, THC, or Grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with high amount of THC
Study: NCT04856566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug with no THC
Study: NCT04856566
Drug: 0.05 BAC Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amount of alcohol when consumed leads to BAC of 0.05
Study: NCT04856566
Drug: 0.08 BAC Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amount of alcohol when consumed leads to BAC of 0.08
Study: NCT04948645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01452698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.
Study: NCT01452698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
Study: NCT05577507
Drug: Calcium Carbonate 500 MG Oral Tablet
Normalized name: Calcium Carbonate 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group will administer standard therapy calcimate 500 mg three times daily within meals
Study: NCT05122338
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT06003972
Drug: guideline directed medical therapy (GDMT)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDMT for heart failure according to the AHA guidelines.
Study: NCT03105843
Drug: Methacholine (MCh) Challenge Testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
Study: NCT06519604
Drug: Human Insulin Injection in dose 5IU
Normalized name: insulin, regular, human Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration of Human Insulin Injection in dose 5IU
Study: NCT05695378
Drug: KM-819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive KM-819 400 mg orally daily.
Study: NCT05695378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo orally daily.
Study: NCT01189032
Drug: Placebo ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02217826
Drug: DG3173
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05261126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching enclitide chloride administered orally
Study: NCT05295810
Drug: Sequential Gas Delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Study: NCT05340465
Drug: Low Molecular Weight Iron Dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
Study: NCT05715099
Drug: Saffron
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: saffron supplement for IBD
Study: NCT05715099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement: placebo for IBD
Study: NCT05781906
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D7: HMPL-523 Tablet 300 mg QD
Study: NCT05781906
Drug: 150 µCi [14C]HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
Study: NCT06262594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is administered
Study: NCT05808231
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care for COVID-19 mild and moderate symptom
Study: NCT04467593
Drug: Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
Study: NCT04162756
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered per package insert
Study: NCT05481151
Drug: P1101 (Ropeginterferon alfa-2b-njft)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon alfa-2b-njft
Study: NCT05494190
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 po bid day 1-14
Study: NCT06601114
Drug: Paracetamol Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
Study: NCT06601114
Drug: Ibuprofen group
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
Study: NCT05084118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: continous application of isotone saline solution for 72 hours
Study: NCT06308523
Drug: AP303 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 Tablet 150 μg QD
Study: NCT06308523
Drug: Placebo 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet 150 μg QD
Study: NCT06308523
Drug: AP303 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP303 Tablet 300 μg QD
Study: NCT06308523
Drug: Placebo 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet 300 μg QD
Study: NCT06724952
Drug: MTX S.C or IM and Silymarin 140 mg tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.
Study: NCT06724952
Drug: MTX S.C or IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM or SC Methotrexate plus placebo tablet once daily for 3 months.
Study: NCT06724653
Drug: RAS blocker tapering group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS blocker tapering out
Study: NCT05878561
Drug: Fimasartan + Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a fixed dose combination
Study: NCT05878561
Drug: Fimasartan + Indapamide placebo
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a fixed dose combination
Study: NCT05929066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06315491
Drug: CBX-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
Study: NCT06722729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06603857
Drug: Sham Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle serum regimen combined with laser treatment
Study: NCT06590194
Drug: PH009-1 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH009-1 will be administered in fasting state
Study: NCT05678881
Drug: placebo inhaled powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhaled powder
Study: NCT06159608
Drug: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
Study: NCT04833582
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c3 is an investigational drug.
Study: NCT05165771
Drug: Placebo to match GS-5718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally